Deals, pipeline readouts and company news from across biotech and pharma.
The US pathogen-reduction specialist posted $57.7 million in third-quarter product revenue and announced positive topline Phase 3 results for its INTERCEPT system for red blood cells.
Jazz Pharmaceuticals reported Q3 2026 revenue of $1.24bn, up 10%, and raised its full-year outlook, while booking a GAAP net loss driven by a $754m IPR&D charge.
The company also reported finished pricing talks in Germany and Italy, an Australian filing, and early lesion regression in three Gorlin syndrome patients treated with KB113.
Auvelity, Sunosi and Symbravo together generated $259.7m in the quarter, while the company narrowed its net loss to $12.9m and began a Phase 3 trial of AXS-05 in smoking cessation.
The US Bankruptcy Court for the District of Delaware has approved the sale of BioXcel's purchased assets to Teva Pharmaceuticals International GmbH, free and clear of liens and claims.
The MRI-compatible infusion pump maker also lifted net income 17% to $6.5m, narrowed its full-year revenue guidance and declared a $0.20 quarterly dividend.
Pelthos Therapeutics has signed a merger agreement with Castle Creek Biosciences, offering shares and milestone payments tied to FDA approval of the orphan-designated cell therapy D-Fi.
The company reported Q3 revenue of $83.7 million, up 14%, and has begun a US Phase 4 study of Lupkynis combined with three other lupus nephritis therapies.
The US life-sciences services group has signed an exclusive licence and made an acquisition to widen GENEWIZ's gene synthesis offering for antibody discovery, protein engineering and AI-enabled drug discovery.
The antibody discovery company reported third-quarter revenue of $4.0M and a $15.7M net loss, while lifting full-year revenue and year-end cash forecasts.
Regeneron reports $5.1bn third-quarter revenue, widens its Sanofi antibody collaboration with a $1.0bn up-front payment, and notes FDA approval of Pasatru for fibrodysplasia ossificans progressiva.
The US home and community health and pharmacy group reported higher third-quarter earnings, lower leverage and an upgraded full-year outlook following the March sale of its Community Living business.
The spine surgery company blamed weaker biologics attachment for the shortfall and now expects full-year revenue of about $862 million.
Merit Medical bought the remaining equity in Solo Pace, its exclusive distributor partner, bringing the FDA-cleared SOLO PACE CONTROL and FUSION pacing systems in-house.
The packaging and drug-delivery supplier reported 1% core growth in Pharma, or 8% excluding emergency medicine destocking, and raised its quarterly dividend to $0.50.
The transplant diagnostics company reported GAAP net income of $19 million for Q3 and said its AlloHeme test remains on track for a planned launch in the first quarter of 2027.
The rare disease company's October corporate deck sets out 2026 revenue and cost guidance, reports $2.1bn in cash and names Phase 3 votoplam in Huntington's disease as a priority.
The company also bought Fabry gene therapy ST-920 for $111m upfront, while the FDA meeting on votoplam in Huntington's disease has slipped to the first quarter of 2027.
Gilead reports Q3 product sales of $8.3bn, driven by HIV growth, and lifts full-year guidance while noting a new FDA approval and wider voluntary licensing for lenacapavir.
The US drugmaker reported third-quarter revenue of $226.8 million, as the FDA recognised orphan exclusivity for ONAPGO and the Indivior merger approaches its expected 2 November close.
BridgeBio's third-quarter revenue was lifted by US Attruby sales and a Bayer milestone, while three priority-review FDA decisions and two EMA reviews approach.
The company reported higher third-quarter sales, held its 2026 revenue guidance and lowered its tax-rate outlook, with a March 2027 FDA action date set for zanzalintinib.
Alnylam reports $1,292m in global net product revenue for Q3 2026, widens its Phase 3 nucresiran study in ATTR-CM and flags a pivotal Huntington's programme for 2027.
The breast aesthetics medtech reported US sales up 119% and its first quarter of positive operating and free cash flow, with FDA review of Motiva for reconstruction on track.
Indivior's third-quarter revenue rose 13% to $356m, driven by a 22% rise in Sublocade sales, with the all-stock Supernus deal expected to complete on 2 November.
The contract research organisation reported $691.5M in third-quarter revenue and narrowed its 2026 guidance, lifting the midpoints for both revenue and adjusted EBITDA.
The maker of semiconductor-based ultrasound devices reported a record 73% gross margin and a narrower net loss, and said it has secured FedRAMP authorization.
The technology services provider reported third-quarter revenue of $5.66 billion, raised its Project Leap restructuring cost estimate and announced a five-year extension of its work with Gilead Sciences.
Bristol Myers Squibb lifted its full-year revenue outlook as Growth Portfolio sales rose 12%, citing the approval of Zenbexus and positive late-stage iza-bren data.
The US company's 29 October presentation addresses commercial progress for ARIKAYCE and BRINSUPRI and clinical updates on TPIP, though the available excerpt gives no financial figures.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.